$OVID

Ovid Therapeutics Inc.

Ovid Therapeutics is a biopharmaceutical company developing small molecule medicines for brain disorders, with a focus on neuronal hyperexcitability. Its pipeline includes clinical-stage programs for drug-resistant focal onset seizures, developmental and epileptic encephalopathies, psychosis associated with Parkinson’s disease and Lewy body dementia, and schizophrenia, as well as preclinical programs for other psychosis and mood disorders. Key programs include OV329, a GABA-aminotransferase inhibitor, and OV4071 and other compounds that directly activate the potassium-chloride cotransporter KCC2. Ovid develops medicines through research and development, in-licensing compounds, and collaborations with academic research centers and other partners. It seeks to create potential revenue through clinical and commercial milestones, strategic collaborations and partnerships, and eventual marketing of medicines. Ovid is headquartered in New York, New York.

No enriched coverage for $OVID in the last 7 days.

No SEC Form 4 filings for $OVID in the last 30 days.

See all $OVID insider activity →

Ovid Therapeutics Reports Business Updates and Third Quarter 2026 Financial Results

Ovid Therapeutics Inc. (OVID) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Ovid Therapeutics Reports Business Updates and Third Quarter 2026 Financial Results • OV329 is advancing in a global, Phase 2 focal epilepsy study expected to read out in H2 2027 • Ovid is enrolling patients in ongoing photosensitivity study intended to demonstrate t

Dissecting Algorithms of the Mind: Toward Precision Psychiatry in Schizophrenia

Experts discussed advancements in precision psychiatry for schizophrenia, including computational phenotyping and new drugs. Brannan highlighted xanomeline-trospium (Cobenfy), approved in 2024, showing significant symptom reduction. Gopal noted patient improvements, while Zhong presented preclinical data on OV4071. Key companies involved: Karuna Therapeutics (Cobenfy), Ovid Therapeutics (OV4071).

OVID sentiment & insider activity

Recent OVID coverage spans financial news, earnings and market movers.

What's driving OVID

AlphAI scores every news story that mentions OVID with an AI model for sentiment and relevance, and aggregates insider trades from Ovid Therapeutics Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $OVID

Score
$OVIDMedEarnings

Ovid Therapeutics Reports Business Updates and Third Quarter 2026 Financial Results

Ovid Therapeutics Inc. (OVID) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Ovid Therapeutics Reports Business Updates and Third Quarter 2026 Financial Results • OV329 is advancing in a global, Phase 2 focal epilepsy study expected to read out in H2 2027 • Ovid is enrolling patients in ongoing photosensitivity study intended to demonstrate t

Dissecting Algorithms of the Mind: Toward Precision Psychiatry in Schizophrenia

Experts discussed advancements in precision psychiatry for schizophrenia, including computational phenotyping and new drugs. Brannan highlighted xanomeline-trospium (Cobenfy), approved in 2024, showing significant symptom reduction. Gopal noted patient improvements, while Zhong presented preclinical data on OV4071. Key companies involved: Karuna Therapeutics (Cobenfy), Ovid Therapeutics (OV4071).

Ovid Therapeutics (OVID) Cashes In One Bet To Fund Its Next Two

Ovid Therapeutics (OVID) reported Q2 results with $169.8M cash, funding operations into 2029. Progress on OV4071 and OV329 clinical trials. R&D expenses rose to $10M, net loss widened to $15M. Soticlestat deal brings potential $294.5M in milestones and royalties. Share count increased after warrant exercises.

After-hours Gainers: HOWL Jumps 90%, MODD To Begin Pivot Pump Rollout, BIVI Awaits Long COVID Data

Werewolf Therapeutics (HOWL) rose 90% in after-hours trading, with key clinical trials ongoing. GeoVax (GOVX) gained 12.66%, preparing for a pivotal Phase 3 study. Greenwich LifeSciences (GLSI) increased 6.27%, extending share lock-up. Modular Medical (MODD) up 7.87%, planning Pivot pump rollout. Ovid Therapeutics (OVID) rose 6.93%, with multiple clinical milestones. BioVie (BIVI) up 4.84%, awaiting long COVID data.

Ovid Therapeutics Strengthens Executive Leadership Team to Support Continued Pipeline Progress and Next Phase of Development

Ovid Therapeutics (Nasdaq: OVID) announced executive leadership changes to support its pipeline. Kevin Norrett will become Chief Business Officer, Charles Carter promoted to CFO, Eliseo Salinas joins as Executive R&D Advisor, and Victoria Fort promoted to Chief Strategy Officer. The company cited ongoing development of OV329 and KCC2 activators and said cash runway extends into 2029.

$OVIDLowExec change· appointed

Ovid Therapeutics Inc. (OVID): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Ovid Therapeutics Inc. (OVID) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. ovid-20260707 0001636651 false 0001636651 2024-03-08 2024-03-08 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported):

Related tickers